Biotech dealmaking

A closer look into biotech dealmaking

In recent quarters, dealmaking has picked up noticeably, despite there not being any big-ticket acquisitions. The cash holdings of several large pharmaceutical companies have also swelled, giving them greater resources to pursue dealmaking.

INCLUDED IN THIS TRENDLINE

After a lengthy drought, could biotech M&A be on the upswing?
The top questions facing biotech M&A in 2022
Venture investors turn to safer bets after biotech correction

Unlock the free Trendline by BioPharma Dive

First Name*

Last Name*

Email Address*

Company Name*

Country*

City*

Yes, I'd like to sign up for the BioPharma Dive newsletter. You can unsubscribe at any time.

By completing this form, you accept the Terms of Use and Privacy Policy You also agree to having your information shared with our sponsor, Thermo Fisher Scientific.*